CY1120860T1 - 2,4 υποκατεστημενες πυριμιδινδιαμινες για χρηση στον δισκοειδη λυκο - Google Patents

2,4 υποκατεστημενες πυριμιδινδιαμινες για χρηση στον δισκοειδη λυκο

Info

Publication number
CY1120860T1
CY1120860T1 CY181100935T CY181100935T CY1120860T1 CY 1120860 T1 CY1120860 T1 CY 1120860T1 CY 181100935 T CY181100935 T CY 181100935T CY 181100935 T CY181100935 T CY 181100935T CY 1120860 T1 CY1120860 T1 CY 1120860T1
Authority
CY
Cyprus
Prior art keywords
pyrimidindiamines
wolf
substituted
disc
lupus erythematosus
Prior art date
Application number
CY181100935T
Other languages
English (en)
Inventor
Daniel Magilavy
Polly Pine
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of CY1120860T1 publication Critical patent/CY1120860T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Οι ενώσεις I και II καθώς και άλατα και φαρμακευτικές συνθέσεις που τις περιέχουν είναι χρήσιμες για τη θεραπεία νόσων και/ή διαταραχών του δέρματος, όπως δερματικός λύκος, για παράδειγμα οξύς δερματικός ερυθηματώδης λύκος, υποξύς δερματικός ερυθηματώδης λύκος, ή δισκοειδής ερυθηματώδης λύκος. Σε συγκεκριμένες εφαρμογές, οι ενώσεις παρέχονται σε τοπικές συνθέσεις.
CY181100935T 2011-03-10 2018-09-06 2,4 υποκατεστημενες πυριμιδινδιαμινες για χρηση στον δισκοειδη λυκο CY1120860T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161451531P 2011-03-10 2011-03-10
PCT/US2012/028429 WO2012122452A1 (en) 2011-03-10 2012-03-09 2,4 substituted pyrimidinediamines for use in discoid lupus

Publications (1)

Publication Number Publication Date
CY1120860T1 true CY1120860T1 (el) 2019-12-11

Family

ID=45922810

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181100935T CY1120860T1 (el) 2011-03-10 2018-09-06 2,4 υποκατεστημενες πυριμιδινδιαμινες για χρηση στον δισκοειδη λυκο

Country Status (21)

Country Link
US (2) US8497279B2 (el)
EP (1) EP2683385B1 (el)
JP (1) JP6121917B2 (el)
KR (1) KR101802011B1 (el)
CN (1) CN103533938A (el)
AU (1) AU2012225367B2 (el)
BR (1) BR112013023052A2 (el)
CA (1) CA2866460C (el)
CY (1) CY1120860T1 (el)
DK (1) DK2683385T3 (el)
EA (1) EA030249B1 (el)
ES (1) ES2686532T3 (el)
HR (1) HRP20181286T1 (el)
HU (1) HUE039486T2 (el)
LT (1) LT2683385T (el)
MX (1) MX343517B (el)
PL (1) PL2683385T3 (el)
PT (1) PT2683385T (el)
RS (1) RS57672B1 (el)
SI (1) SI2683385T1 (el)
WO (1) WO2012122452A1 (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US9040061B2 (en) * 2011-12-08 2015-05-26 Rigel Pharmaceuticals, Inc. Topical formulation for administering a compound
JP2015528501A (ja) * 2012-09-12 2015-09-28 ライジェル ファーマシューティカルズ， インコーポレイテッド 白斑の治療法
CN107805212B (zh) * 2017-11-03 2021-08-20 宿迁德威化工股份有限公司 一种2-甲基-5-氨基苯磺酰胺的制备方法
WO2021113410A1 (en) * 2019-12-02 2021-06-10 Ampersand Biopharmaceuticals, Inc. Transdermal penetrant formulations for vitamins, minerals and supplements

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US296006A (en) 1884-04-01 John hoefleb
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
JPS6069037A (ja) 1983-09-26 1985-04-19 Sunstar Inc エリテマト−デス治療用外用剤
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1261849B (it) 1993-09-02 1996-06-03 Avantgarde Spa Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici.
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US5965154A (en) 1998-03-17 1999-10-12 Plc Holding, L.L.C. Adhesive matrix type transdermal patch and method of manufacturing same
ATE451104T1 (de) 2002-07-29 2009-12-15 Rigel Pharmaceuticals Inc Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen
WO2006133426A2 (en) * 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US8013120B2 (en) 2005-10-26 2011-09-06 Stc.Unm C-reactive protein and its use to treat systemic lupus erythematosus and related conditions
ES2562428T3 (es) 2005-12-15 2016-03-04 Rigel Pharmaceuticals, Inc. Inhibidores de cinasa y sus usos

Also Published As

Publication number Publication date
ES2686532T3 (es) 2018-10-18
US20130274277A1 (en) 2013-10-17
EA201391304A1 (ru) 2014-05-30
EP2683385A1 (en) 2014-01-15
MX343517B (es) 2016-11-07
LT2683385T (lt) 2018-10-25
BR112013023052A2 (pt) 2017-07-25
CA2866460A1 (en) 2012-09-13
DK2683385T3 (en) 2018-09-17
KR20140025377A (ko) 2014-03-04
CN103533938A (zh) 2014-01-22
AU2012225367A1 (en) 2013-10-24
WO2012122452A1 (en) 2012-09-13
PL2683385T3 (pl) 2018-12-31
CA2866460C (en) 2021-03-09
HUE039486T2 (hu) 2019-01-28
SI2683385T1 (sl) 2018-11-30
US8497279B2 (en) 2013-07-30
PT2683385T (pt) 2018-10-19
RS57672B1 (sr) 2018-11-30
AU2012225367B2 (en) 2017-05-25
HRP20181286T1 (hr) 2018-10-05
EA030249B1 (ru) 2018-07-31
EP2683385B1 (en) 2018-06-06
KR101802011B1 (ko) 2017-11-27
JP6121917B2 (ja) 2017-04-26
JP2014507480A (ja) 2014-03-27
MX2013010308A (es) 2013-12-02
US20120232106A1 (en) 2012-09-13

Similar Documents

Publication Publication Date Title
CY1120860T1 (el) 2,4 υποκατεστημενες πυριμιδινδιαμινες για χρηση στον δισκοειδη λυκο
CY1122919T1 (el) Διεγερτες sgc
CY1125279T1 (el) Ετεροκυκλικοι αναστολεις γλουταμινασης
CY1122186T1 (el) Μεθοδοι θεραπειας καρκινου
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
CY1120318T1 (el) Υποκατεστημενες βενζυλινδαζολες για χρηση ως αναστολεις κινασης bub1 στη θεραπευτικη αντιμετωπιση υπερπολλαπλασιαστικων ασθενειων
CY1122480T1 (el) Μεθυλικη βαρδοξολονη για τη θεραπεια παχυσαρκιας
CY1120337T1 (el) Θειοοξικες ενωσεις, συνθεσεις και μεθοδοι χρησης
CY1121858T1 (el) Παραγωγα αρυλμεθοξυ ισοϊνδολινης και συνθεσεις που περιλαμβανουν αυτες και μεθοδοι χρησης αυτων
CY1121413T1 (el) Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα
CY1120862T1 (el) Παραγοντες επαγωγης αποπτωσης για τη θεραπευτικη αγωγη καρκινου και ανοσων και αυτοανοσων ασθενειων
CY1118129T1 (el) 5-αλκυνυλ-πυριμιδινες
CY1117986T1 (el) Ενωσεις αρυλ- ή ετεροαρυλ-υποκατεστημενου βενζολιου
CY1119123T1 (el) Δις-αρυλοσυζευγμενες αρυλοτριαζολονες και η χρηση τους
CY1118187T1 (el) Χημικες ενωσεις
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
ECSP12012326A (es) Derivados de aminopirimidina como moduladores de la lrrk2
BR112015020804A2 (pt) dispositivo fototerapeutico, método e uso
CY1123216T1 (el) Αναστολεις της gls1 για την αντιμετωπιση νοσων
PE20151023A1 (es) Triazolopirazinas
EA201391106A1 (ru) Новые гетероциклические производные
UY34775A (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis múltiple
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
CY1122818T1 (el) Παραγωγα 3-((ετερο-)αρυλ)-αλκυλ-8-αμινο-2-οξο-1,3-διαζα- σπε1ρο-[4.5]-δεκανιου